ESMO 2017 Highlights in Breast Cancer: Further Progress in ER+/HER2- Disease - Cancer
Aleix Prat points out the importance of the results presented during the ESMO 2017 Congress for the breast cancer community. Angelo Di Leo explains that the MONARCH 3 study was designed to determine whether we can improve the activity of endocrine therapy by combining it with CDK4-6 inhibitor therapy in ER+/HER2- advanced breast cancer patients. As expected, the combination improves the efficacy both clinically and statistically, with an observed 46% decrease in risk of progression. Paul Cottu shows in the NeoPAL study that endocrine therapy plus CDK4/6 inhibition is not better than neoadjuvant chemotherapy in luminal stage II/III ER+/HER2- breast